| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
462,934 |
391,927 |
$34.12M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
320,314 |
282,102 |
$19.89M |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
137,931 |
128,084 |
$5.28M |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
37,388 |
35,295 |
$4.28M |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
31,999 |
30,143 |
$3.59M |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
25,240 |
22,840 |
$2.78M |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
15,060 |
14,172 |
$1.80M |
| 96127 |
|
67,906 |
61,066 |
$1.23M |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
25,995 |
23,240 |
$1.10M |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
13,369 |
12,629 |
$902K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
32,377 |
30,156 |
$561K |
| 80061 |
Lipid panel |
41,219 |
35,262 |
$352K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
18,246 |
16,895 |
$339K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
13,367 |
12,628 |
$301K |
| 80053 |
Comprehensive metabolic panel |
40,604 |
35,379 |
$287K |
| 95810 |
Polysomnography; sleep staging with 4 or more additional parameters |
936 |
685 |
$225K |
| 31231 |
|
3,030 |
2,543 |
$212K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
2,888 |
2,579 |
$190K |
| 99215 |
Prolong outpt/office vis |
1,813 |
1,439 |
$171K |
| 95806 |
|
1,816 |
1,579 |
$162K |
| 99177 |
|
8,723 |
8,245 |
$155K |
| 84443 |
Thyroid stimulating hormone (TSH) |
13,030 |
11,418 |
$153K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
3,854 |
3,452 |
$150K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
26,138 |
22,743 |
$139K |
| 36416 |
|
44,963 |
41,736 |
$135K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
5,988 |
5,101 |
$118K |
| 99243 |
|
1,365 |
1,323 |
$112K |
| 36415 |
Collection of venous blood by venipuncture |
51,445 |
43,553 |
$108K |
| 99173 |
|
13,239 |
12,358 |
$87K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
13,820 |
11,727 |
$82K |
| 92558 |
|
3,416 |
3,214 |
$75K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
6,372 |
5,797 |
$59K |
| 83655 |
|
5,626 |
5,350 |
$59K |
| 90674 |
|
13,732 |
12,861 |
$57K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
4,108 |
3,643 |
$57K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
2,018 |
1,826 |
$56K |
| 99308 |
Subsequent nursing facility care, per day, straightforward |
2,747 |
2,465 |
$56K |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
668 |
593 |
$53K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
1,715 |
1,379 |
$51K |
| 92551 |
|
8,324 |
7,842 |
$47K |
| 96161 |
|
2,305 |
2,063 |
$47K |
| 92557 |
|
2,325 |
1,972 |
$46K |
| 31575 |
|
926 |
814 |
$40K |
| 99309 |
Subsequent nursing facility care, per day, low to moderate complexity |
1,545 |
1,395 |
$38K |
| 92583 |
|
1,870 |
1,723 |
$37K |
| 99244 |
Office or other outpatient consultation, moderate to high complexity |
328 |
313 |
$36K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
545 |
437 |
$34K |
| 0071A |
|
1,009 |
867 |
$33K |
| 0072A |
|
983 |
856 |
$33K |
| 90686 |
|
68,832 |
64,835 |
$32K |
| 99442 |
|
1,264 |
1,111 |
$32K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
1,722 |
1,373 |
$30K |
| 99051 |
|
5,947 |
5,347 |
$30K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
270 |
235 |
$25K |
| 80050 |
General health panel |
1,009 |
839 |
$25K |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
1,571 |
1,460 |
$24K |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
14,697 |
11,863 |
$24K |
| 94760 |
|
16,458 |
14,683 |
$24K |
| 92552 |
|
1,902 |
1,821 |
$22K |
| 90480 |
|
666 |
643 |
$21K |
| 93000 |
|
1,823 |
1,587 |
$18K |
| 82607 |
|
1,618 |
1,359 |
$16K |
| 90682 |
|
758 |
598 |
$16K |
| 96160 |
|
955 |
783 |
$16K |
| 69210 |
|
1,558 |
1,271 |
$14K |
| 99307 |
|
909 |
756 |
$13K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
401 |
383 |
$12K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
387 |
369 |
$12K |
| 99443 |
|
244 |
219 |
$10K |
| 99406 |
|
919 |
812 |
$9K |
| 31579 |
|
129 |
104 |
$9K |
| 84439 |
|
1,394 |
1,238 |
$9K |
| 91320 |
|
170 |
162 |
$9K |
| 86803 |
|
765 |
693 |
$8K |
| 95811 |
|
41 |
28 |
$8K |
| 90677 |
|
1,637 |
1,550 |
$8K |
| 81001 |
|
3,502 |
3,044 |
$7K |
| 82043 |
|
1,821 |
1,549 |
$6K |
| 99306 |
Prolong nursin fac eval 15m |
101 |
93 |
$6K |
| 99381 |
|
61 |
48 |
$5K |
| 87070 |
|
727 |
679 |
$5K |
| 90651 |
|
1,286 |
1,246 |
$4K |
| 96111 |
|
45 |
31 |
$4K |
| 92504 |
|
379 |
300 |
$4K |
| 82570 |
|
1,247 |
982 |
$3K |
| 99347 |
|
173 |
137 |
$3K |
| 83718 |
|
450 |
434 |
$3K |
| 87634 |
|
50 |
42 |
$3K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
266 |
238 |
$2K |
| 92567 |
|
319 |
266 |
$2K |
| 92550 |
|
408 |
365 |
$2K |
| 99174 |
|
118 |
117 |
$2K |
| 99441 |
|
860 |
788 |
$2K |
| 87081 |
|
333 |
327 |
$2K |
| 82465 |
|
439 |
423 |
$2K |
| 90662 |
|
676 |
527 |
$1K |
| 0001A |
|
79 |
42 |
$1K |
| 85018 |
|
28,155 |
26,742 |
$1K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
199 |
195 |
$1K |
| 85027 |
|
292 |
243 |
$1K |
| 99304 |
|
31 |
27 |
$1K |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
62 |
62 |
$1K |
| 0124A |
|
29 |
24 |
$960.00 |
| 84480 |
|
120 |
85 |
$902.06 |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
18 |
14 |
$709.12 |
| 87807 |
|
65 |
62 |
$675.55 |
| 82728 |
|
55 |
53 |
$586.53 |
| 96380 |
|
47 |
47 |
$574.56 |
| 82746 |
|
43 |
41 |
$519.48 |
| 84436 |
|
132 |
97 |
$495.64 |
| G0179 |
Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and allowed practitioners to affirm the initial implementation of the plan of care |
51 |
50 |
$488.53 |
| 90653 |
|
115 |
113 |
$488.40 |
| 0112A |
|
12 |
12 |
$480.00 |
| 83550 |
|
67 |
65 |
$466.91 |
| 99050 |
|
31 |
31 |
$450.24 |
| 0154A |
|
12 |
12 |
$440.00 |
| 0111A |
|
25 |
13 |
$440.00 |
| 0002A |
|
23 |
13 |
$440.00 |
| 90732 |
|
32 |
31 |
$431.00 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
56 |
53 |
$373.96 |
| 83540 |
|
67 |
65 |
$345.20 |
| 80305 |
|
54 |
53 |
$309.55 |
| 82550 |
|
86 |
64 |
$263.40 |
| G8431 |
Screening for depression is documented as being positive and a follow-up plan is documented |
47 |
28 |
$259.20 |
| 94060 |
|
17 |
12 |
$255.78 |
| 83735 |
|
50 |
41 |
$237.95 |
| 94761 |
|
69 |
66 |
$204.80 |
| 90688 |
|
18 |
14 |
$196.24 |
| 81002 |
|
2,291 |
2,120 |
$194.04 |
| G0439 |
Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit |
238 |
183 |
$176.73 |
| 82962 |
|
145 |
100 |
$145.88 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
20 |
13 |
$139.60 |
| 84450 |
|
50 |
46 |
$134.82 |
| 90734 |
|
440 |
427 |
$115.55 |
| 84460 |
|
65 |
61 |
$114.18 |
| 94762 |
|
19 |
12 |
$113.61 |
| 82947 |
|
77 |
64 |
$105.00 |
| 90785 |
|
48 |
31 |
$103.04 |
| 85652 |
|
38 |
36 |
$82.98 |
| 81003 |
|
319 |
293 |
$78.46 |
| 82044 |
|
44 |
41 |
$61.18 |
| 85007 |
|
14 |
14 |
$45.92 |
| 82248 |
|
19 |
14 |
$44.73 |
| 88738 |
|
209 |
196 |
$36.40 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
240 |
216 |
$11.05 |
| G0008 |
Administration of influenza virus vaccine |
2,117 |
1,818 |
$2.30 |
| G0009 |
Administration of pneumococcal vaccine |
27 |
26 |
$0.01 |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
119 |
30 |
$0.01 |
| 90723 |
|
3,255 |
3,108 |
$0.00 |
| 90680 |
|
4,200 |
4,045 |
$0.00 |
| 1170F |
|
916 |
872 |
$0.00 |
| 90647 |
|
3,083 |
2,968 |
$0.00 |
| 90698 |
|
1,883 |
1,807 |
$0.00 |
| 91307 |
|
2,813 |
2,398 |
$0.00 |
| 91305 |
|
164 |
75 |
$0.00 |
| 99000 |
|
513 |
463 |
$0.00 |
| 90697 |
|
456 |
436 |
$0.00 |
| 90619 |
|
202 |
191 |
$0.00 |
| 90744 |
|
205 |
198 |
$0.00 |
| 1126F |
|
173 |
164 |
$0.00 |
| 90716 |
|
317 |
307 |
$0.00 |
| 90666 |
|
146 |
137 |
$0.00 |
| 4037F |
|
18 |
16 |
$0.00 |
| 90696 |
|
63 |
53 |
$0.00 |
| 99024 |
|
22 |
12 |
$0.00 |
| 1125F |
|
31 |
30 |
$0.00 |
| G2024 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source |
150 |
143 |
$0.00 |
| 90632 |
|
12 |
12 |
$0.00 |
| 91300 |
|
271 |
230 |
$0.00 |
| 90670 |
|
10,052 |
9,652 |
$0.00 |
| 90661 |
|
8,831 |
8,692 |
$0.00 |
| 1160F |
|
2,024 |
1,876 |
$0.00 |
| 90685 |
|
1,463 |
1,378 |
$0.00 |
| 1159F |
|
2,024 |
1,876 |
$0.00 |
| 90707 |
|
344 |
333 |
$0.00 |
| 90648 |
|
920 |
880 |
$0.00 |
| 90633 |
|
1,955 |
1,857 |
$0.00 |
| 91321 |
|
208 |
204 |
$0.00 |
| 90710 |
|
175 |
170 |
$0.00 |
| 90672 |
|
13 |
13 |
$0.00 |
| 91312 |
|
29 |
24 |
$0.00 |
| 90621 |
|
12 |
12 |
$0.00 |
| 91311 |
|
84 |
61 |
$0.00 |
| 90681 |
|
42 |
41 |
$0.00 |
| 90715 |
|
12 |
12 |
$0.00 |
| 90700 |
|
13 |
13 |
$0.00 |